Navigation Links
Brazilian Women to Be Vaccinated To Prevent Uterine Cancer

Human Papilloma virus is a major cause of uterine cancer. According to the statistics it was found that the HPV causes 70 % of Brazil’s uterine cancer cases//. Hence the Brazilian government plans to test the new Gardasil vaccine which treats HPV. After the positive test results then the government plans to release the vaccine in the market. Brazilian health officials are planning to conduct a campaign to vaccinate Brazilian women against the human Papilloma virus (HPV).

Luiz Antonio Santini, director of Brazil's National Cancer Institute said that about 50 % of the sexually active women in Brazil have the virus. The vaccine is waiting approval from the National Sanitary Vigilance Agency (Anvisa) for sale in Brazil. Prior to that the Brazil's health authorities plan to conduct a study to find out what types of HPV are most common in different regions of the country. The vaccine has already been approved for sale in US and it costs about 120 U.S. dollars. Patients have to receive three doses of the vaccination to make it effective. The vaccine is very costly as of now but its price would reduce if the production increased.


'"/>




Page: 1

Related medicine news :

1. Brazilian Boost for Bird Flu Vaccines
2. Women suffer from sexual dysfunction too
3. Women find difficulty in calling it Quits
4. Women recognise faces better
5. Women more susceptible to brain damage from ecstasy
6. Good News For Women With Gestational Diabetes
7. Unsatisfactory Grade On Womens Health Issues
8. Risk for Pregnant Women
9. Womens strong sense of smell
10. Women need to exercise more to prevent obesity
11. Women benefit from consuming fish
Post Your Comments:
(Date:12/5/2008)...yzoom provides physicians and their office manager... Columbus, OH (PRWEB) Decemb...as launched Phase I of PHYZOOM, a suite of web-bas...icians, PHYZOOM offers numerous practice marketing...sician and practice profiles, easy to use blogging...
(Date:12/4/2008)...swire-USNewswire/ -- In the 1983 movie "A Christma...hat a Red Ryder BB gun is the perfect gift. , ... he got from his parents, teacher and even Santa C... quotes from this Christmas classic because we,ve ...unfortunately, it comes true for too many people. ...
(Date:12/4/2008)... people over a 20-year period suggests your smile ..., Dec. 4 (HealthDay News) -- Happy friends can mak...iends. , That,s the unusual conclusion of a new...et can have an impact on each other,s feelings. ,...le we,re directly connected to," said study co-aut...
(Date:12/4/2008)...re-USNewswire/ -- The U.S. Government, through the..., is providing an additional $600,000 to help comb...nce is in addition to the $4 million water, sanita...dy implementing in Zimbabwe. , , "Before ch...the international community to prepare for the pos...
Breaking Medicine News(10 mins):Health News:OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product 2Health News:OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product 3Health News:Texas Parents Can Prevent Holiday Tragedies with Safe Toys and Celebrations 2Health News:Being Happy Affects Even Those You Don't Know 2Health News:Being Happy Affects Even Those You Don't Know 3Health News:USAID Increases Assistance for Zimbabwe Cholera Outbreak 2
...rd researchers suggests a link between the hepatit...study, people who received the vaccine were three-...hree years than those who were not vaccinated. Whi...tigators emphasize the overall effect of the vacci...
... an increased risk for life-threatening cardiovasc...etes would be well // advised to monitor their blo..., according to a new study. Researchers conducted ...ed observational studies focused on the relationsh...
...itis in asthma patients tends to be more severe an...hers suggest patients // can have dramatic improve...surgical options is used. In the study patients wi...cidence of nasal polyps, olfactory dysfunction, an...
... designed to educate parents about allergens and t...in children // say researchers .More than 900 ch... allergic to at least one indoor environmental all...earch shows children who live in these areas suffe...
Other Medicine News:
(Date:12/4/2008)...nist to Advance to Clinical Trials , , SAN ...als, Inc., a biopharmaceutical company focused on ...8) agonists for the treatment of cancer, respirato...t has initiated a Phase I clinical trial of VTX-23...cancer. The multi-center clinical trial is being ...
(Date:12/3/2008)...a demonstrating potential in newly diagnosed patie... featured in two oral sessions at ASH , , -...cally transfused patients by significantly reducin... - New long-term data from major independent breas...surgery treatment strategy, Femara vs. tamoxifen ,...
(Date:12/3/2008)...lleviates long-term anemia and organ damage in mic..., MEMPHIS, Tenn., Dec. 3 /PRNewswire-USNewswire... gene into mouse blood cells, scientists at St. Ju...ckle cell disease pathology. In their studies, the...sentially no difference from normal mice. Although...
(Date:12/3/2008)...Newswire/ -- Isogen, a contract development and,m...ounced it has retained a,strategic financial part...l,biopharma demand for Isogen,s services. , ...st round series of capital,investment and the ope... to,deliver on the previously unmet process, faci...
Breaking Medicine Technology:VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Are Muramyl Peptides the Magic Bullet in Probiotics 3F 1038 1Are Muramyl Peptides the Magic Bullet in Probiotics 3F 1038 2Are Muramyl Peptides the Magic Bullet in Probiotics 3F 1038 3With Obesity Diabetes and Cardiovascular Disease on the Rise Physicians Need More Comprehensive Guidelines 8040 1With Obesity Diabetes and Cardiovascular Disease on the Rise Physicians Need More Comprehensive Guidelines 8040 2SGI Introduces the SGI BioCluster Life Sciences Workflow Solution 8037 1SGI Introduces the SGI BioCluster Life Sciences Workflow Solution 8037 2SGI Introduces the SGI BioCluster Life Sciences Workflow Solution 8037 3SGI Introduces the SGI BioCluster Life Sciences Workflow Solution 8037 4InterCure Names Scot Dube Vice President of Sales 8034 1InterCure Names Scot Dube Vice President of Sales 8034 2InterCure Names Scot Dube Vice President of Sales 8034 3
...rgroupe Francophone du Myelome (IFM),Trial Present...PRNewswire-FirstCall/ --,Millennium Pharmaceutical...d on the comparative Phase III clinical trial eval...multiple myeloma (MM),patients. As induction thera...ELCADE based therapy produced a high complete remi...
...-- Ablynx today announced positive,interim results...pment programme, ALX-0081, an anti-thrombotic trea...cute; therapeutic,Nanobody® targeting von Will...thrombosis in patients with acute coronary,syndrom...signed to assess,safety, tolerability and pharmaco...
Other Medicine Technology:Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 2Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 3Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 5Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 6Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2
Soft PVC. Available in sizes 12-36F, Interior striations for smooth suction catheter insertion. Bevel tip. Single use. Sterile.
Smooth flexible medical grade white low density polyethylene with reinforced block to prevent collapse.
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati
Black elastomer. Smooth finish. Non-Sterile.
Medicine Products: